Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / CHRS - FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients | Benzinga

CHRS - FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients | Benzinga

Coherus BioSciences Inc.

The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of Udenyca (pegfilgrastim-cbqv), solely due to an ongoing review of inspection findings at a third-party filler. 

Coherus markets Udenyca (pegfilgrastim-cbqv), a biosimilar of Amgen Inc's (NASDAQ: AMGN) Neulasta, a prescription medicine used to prevent neutropenia (a lack of ...

Full story available on Benzinga.com
Stock Information
Company Name: Coherus BioSciences Inc.
Stock Symbol: CHRS
Market: NASDAQ
Website: coherus.com
Menu
CHRS CHRS Quote CHRS Short CHRS News CHRS Articles CHRS Message Board
Get CHRS Alerts

News, Short Squeeze, Breakout and More Instantly...